A randomised placebo controlled trial of pegylated interferon α in active ulcerative colitis

Gut

Volumn 52, Issue 12, 2003, Pages 1728-1733

  Tilg, H ^a   Vogelsang, H ^a   Ludwiczek, O ^a   Lochs, H ^b   Kaser, A ^a   Colombel, J F ^c   Ulmer, H ^a   Rutgeerts, P ^d   Kruger S ^b   Cortot, A ^c   D'Haens, G ^d   Harrer, M ^a   Gasche, C ^a   Wrba, F ^a   Kuhn, I ^e   Reinisch, W ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Charite ^*  (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Merck Sharp and Dohme GesmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; C REACTIVE PROTEIN; MESALAZINE; PEGINTERFERON ALPHA2B; STEROID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GRAND MAL SEIZURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; THROMBOSIS; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; OROSOMUCOID; POLYETHYLENE GLYCOLS;

EID: 10744225116     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.12.1728     Document Type: Article

References (26)

1. Farrel RJ, Peppercorn MA. Ulcerative colitis. Lancet 2003;359:331-40.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
3. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
4. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
5. Tilg H. New insights into the mechanisms of interferon alfa: An immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112:1017-21.
6. Guttermann JU. Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci U S A 1995;91:1198-205.
7. Tilg H, Mier JW, Vogel W, et al. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 1993;150:4687-92.
8. Tilg H, Vogel W, Dinarello CA. Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. Blood 1995;85:433-5.
9. Schandené L, Del Prete GF, Cogan E, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest 1996;97:309-15.
10. Kaser A, Molnar C, Tilg H. Differential regulation of interleukin 4 and interleukin 13 production by interferon-alpha. Cytokine 1998;10:75-81.
11. Fuss U, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-70.
12. + NK-T cells is increased in oxazolone and human ulcerative colitis (UC). Gastroenterology 2003;124:A35, (abstract 276).
13. Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:597-602.
14. Madsen SM, Schlichting P, Davidsen P, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001;96:1807-15.
15. Rachmilewitz D. Coated mesalazine (5-aminosalicyclic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6.
16. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study. Gastroenterology 1998;115:525-32.
17. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
18. Schindler R, Ghezzi P, Dinarello CA. IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J Immunol 1990;144:2216-22.
19. Huang Y, Blatt LM, Tylor MW. Type I Interferon as an antiinflammatory agent: Inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist. J Interferon Cytokine Res 1995;15:317-21.
20. Oliviera IC, Scuavolino PJ, Lee TH, et al. Downregulation of interleukin-8 gene expression in human fibroblasts: Unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci U S A 1992;89:9043-8.
21. Kaser A, Novick D, Rubinstein M, et al. Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol 2002;129:332-8.
22. Amann MJ, Tretter T, Eisenbeis I, et al. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood 1996;87:4731-6.
23. Gasche C, Reinisch W, Vogelsang H, et al. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci 1995;40:800-4.
24. Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon beta in patients with steroid-refractory active ulcerative colitis: an open long-term pilot trial. Aliment Pharmacol Ther 2002;16:1233-9.
25. Novick D, Cohen B, Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 1994;77:391-400.
26. da Silva AJ, Brickelmaier M, Majeau GR, et al. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b versus IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J Interferon Cytokine Res 2002;22:173-88.